A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Prasinezumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]